An Introduction to Asset Evaluation for Emerging Biotech Companies On-Demand Webinar An Introduction to Asset Evaluation for Emerging Biotech Companies Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…CertaraJanuary 21, 2021
“Where do I start?”: Strategies for selecting the first dose for human clinical trials White Paper “Where do I start?”: Strategies for selecting the first dose for human clinical trials This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…CertaraDecember 22, 2020
The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries Publication The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul…CertaraDecember 22, 2020
Be Honest, Be Reliable, Be Human: Insights from a Global Drug Development Expert Blog Be Honest, Be Reliable, Be Human: Insights from a Global Drug Development Expert One of the most exciting things about working in the pharmaceutical industry is the ability…CertaraDecember 16, 2020
Certara Announces Pricing of its Upsized Initial Public Offering Press Release Certara Announces Pricing of its Upsized Initial Public Offering PRINCETON, NJ.— December 10, 2020 – Certara, Inc. (“Certara”), a global leader in biosimulation, today…CertaraDecember 10, 2020
Certara’s Phoenix software supports training of the next generation of the pharmacometricians in China Press Coverage Certara’s Phoenix software supports training of the next generation of the pharmacometricians in China The Pharmacy department of the Shanghai Chest Hospital is dedicated to developing and applying model-informed…CertaraDecember 3, 2020
Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncology: It takes 2 to tango On-Demand Webinar Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncology: It takes 2 to tango More than 50 bispecific antibodies are in oncology clinical development with a large diversity in…CertaraDecember 2, 2020
Getting Real with RWE Press Coverage Getting Real with RWE By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…CertaraNovember 20, 2020
Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters Publication Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters CertaraNovember 13, 2020